Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00543413 | A Study to Determine the Effectiveness and Tolerability of MK8141 in Patients With High Blood Pressure (MK-8141-006) | PHASE2 | COMPLETED | 160 | — | — | Oct 1, 2007 | Jun 1, 2008 | Oct 16, 2015 | - | — |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Arm 1: Drug 250 mg |
| 2 | EXPERIMENTAL | Arm 2: Drug 500 mg |
| 3 | ACTIVE_COMPARATOR | Arm 3: Active Comparator |
| 4 | PLACEBO_COMPARATOR | Arm 4: Pbo Comparator |
| Name | Type | Description |
|---|---|---|
| MK8141 | DRUG | MK8141 250 mg tablet once daily; 500 mg tablet once daily 4 week treatment period |
| Comparator: placebo (unspecified) | DRUG | MK8141 Pbo tablet once daily. 4 week treatment period. |
| Enalapril | DRUG | Enalapril 20 mg tablet once daily. 4 week treatment period. |
Inclusion Criteria: * You are 35 to 65 years of age * In the past 14 days you have not been treated for hypertension * In the past 14 days you have not taken more than 2 medications to treat high blood pressure * You are a woman who is not able to have children or do not use birth control Exclusio...